A group of some 50 Swiss nationals in China have sent a letter to the Swiss government complaining that they feel forgotten by Swiss authorities during the Covid-19 outbreak.
@ SWI swissinfo.ch | February 19, 2020
A group of some 50 Swiss nationals in China have sent a letter to the Swiss government complaining that they feel forgotten by Swiss authorities during the Covid-19 outbreak.
@ SWI swissinfo.ch | February 19, 2020
Splendris International Limited, an affiliate of Shenzhen Salubris Pharmaceuticals Co Ltd. (Salubris), a multi-national leader in the development and commercialization of cardiovascular products in China and beyond, today announced a strategic investment and in-licensing agreement with Swiss cardiovascular pioneer M.A. MedAlliance S.A. (MedAlliance). Under the terms of the agreement, Salubris will make a $20 million equity investment in MedAlliance and will commit an additional $10 million in developmental milestones in exchange for exclusive rights to develop and commercialize MedAlliance’s lead investigational product Selution, a potential best-in-class sirolimus micro-reservoir drug-coated balloon (DCB), for peripheral and cardiovascular applications in the Chinese market. MedAlliance will also be eligible for royalty payments on sales.
@ Business Wire | May 21, 2018